CHRU departments
Expanding cervical cancer prevention services
The Clinical HIV Research Unit’s Women’s Cancer Prevention Research Program focuses on improving cervical cancer screening, awareness and treatment, specifically among women living with HIV in South Africa.
Background
The highest prevalence of the human papillomavirus (HPV) which causes cervical cancer is among women in sub-Saharan Africa. Despite being preventable, cervical cancer is the most common cause of cancer death among women in the region. In South Africa, cervical cancer is the second most common cancer among women after breast cancer.
The incidence rate of cervical cancer in South Africa is between 22.8-27 per 100 000 women compared to the global average of 15.8 per 100 000.
Women living with Cervical Cancer and HIV are more vulnerable
Women living with HIV are at a higher risk for:
HPV,
cervical pre-cancer and
invasive cervical cancer.
CHRU’s Clinical trials address the HPV and cervical cancer burden
With a focus on women living with HIV, CHRU conduct studies focusing on:
HPV diagnostics,
cervical cancer screening and
cervical pre cancer treatment.
Women’s Cancer Prevention Research Program’s networks and sponsors
Our research is conducted in collaboration with and with the support from:
AIDS Malignancy Consortium (AMC),
CHRU Departments
